VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
XC8
Phase 3
Small molecule
C
Chemlmmune Therapeutics LLC
1
Indications
8
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Acute Respiratory Viral Infections
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Acute Respiratory Viral Infections
Phase 3
Recruiting
Clinical
Trials by Indication
[1]
Tics
3 trials
Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers
Completed
·
V
Valenta Pharm JSC
·
N/A
·
NCT05558462
·
24 enrolled
Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8
Completed
·
E
EURRUS Biotech GmbH
·
Phase 1
·
NCT02882217
·
32 enrolled
XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers
Completed
·
P
PHARMENTERPRISES LLC
·
Phase 1
·
NCT03441815
·
28 enrolled
Asthma
2 trials
XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
Completed
·
C
Chemlmmune Therapeutics LLC
·
Phase 2
·
NCT04674137
·
70 enrolled
XC8 in the Treatment of Patients With Bronchial Asthma
Completed
·
P
PHARMENTERPRISES LLC
·
Phase 2
·
NCT03450434
·
120 enrolled
TED
1 trial
Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets
Completed
·
V
Valenta Pharm JSC
·
Phase 1
·
NCT05294250
·
24 enrolled
Acute Respiratory Viral Infections
1 trial
Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections
Recruiting
·
V
Valenta Pharm JSC
·
Phase 3
·
NCT06379542
·
252 enrolled
Respiratory Viral Infection
1 trial
XC8 in the Treatment of Patients With Acute Respiratory Viral Infection
Completed
·
P
PHARMENTERPRISES LLC
·
Phase 2/3
·
NCT03441373
·
320 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
8 trial records for XC8. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
XC8 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for XC8. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Chemlmmune Therapeutics LLC company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 3
[1]
Company
C
Chemlmmune Therapeutics LLC
Related News